What is Thymox?
Laboratoire M2 operates at the intersection of biotechnology and industrial hygiene, specializing in the development of biodegradable disinfectants derived from thyme oil. The company's flagship Thymox brand provides a comprehensive suite of antimicrobial products effective against a broad spectrum of pathogens, including bacteria, fungi, and viruses. By utilizing thymol as an active ingredient, the firm delivers high-performance sanitation solutions that meet the rigorous demands of modern agriculture, animal husbandry, and hard-surface disinfection. Their business model emphasizes not only product efficacy but also environmental stewardship, positioning them as a leader in the sustainable chemical industry. Through strategic partnerships and a commitment to co-innovation, Laboratoire M2 continues to expand its footprint, offering distributors and industrial partners a viable, non-toxic alternative to conventional chemical agents.
How much funding has Thymox raised?
Thymox has raised a total of $4.6M across 1 funding round:
Series B
$4.6M
Series B (2017): $4.6M with participation from Desjardinsu2013Innovatech and Cycle Capital
Key Investors in Thymox
Desjardins-Innovatech
A prominent Canadian cooperative investment arm associated with the largest federation of credit unions in North America, focusing on regional economic development and sustainable growth.
Cycle Capital
A specialized venture capital firm dedicated to clean technology, managing multiple funds across North America and Europe with a focus on DeepTech and circular innovation.
What's next for Thymox?
With this major enterprise-level funding, Laboratoire M2 is well-positioned to accelerate its international market penetration and deepen its research and development capabilities. The strategic roadmap likely involves scaling production capacity to meet rising global demand for eco-conscious biopesticides and surface disinfectants. Furthermore, the company is expected to leverage this capital to enhance its collaborative ecosystem, inviting new distributors and co-innovators to integrate Thymox technology into broader industrial applications. As the firm matures, the focus will likely shift toward optimizing supply chain efficiencies and securing additional regulatory approvals in key global markets, ensuring that their thymol-based solutions remain at the forefront of the global antimicrobial landscape.
See full Thymox company page
